Cassady Schiller Wealth Management’s Catalyst Pharmaceutical CPRX Stock Holding History

Cassady Schiller Wealth Management’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	$16.7K	Hold	800	–	–	0.01%	298
2024 Q3	$15.9K	Hold	800	–	–	0.01%	292
2024 Q2	$12.4K	Hold	800	–	–	0.01%	302
2024 Q1	$12.8K	Hold	800	–	–	0.01%	323
2023 Q4	$13.4K	Hold	800	–	–	0.01%	310
2023 Q3	$9.35K	Hold	800	–	–	0.01%	335
2023 Q2	$10.8K	Hold	800	–	–	0.01%	332
2023 Q1	$13.3K	Hold	800	–	–	0.01%	304
2022 Q4	$14.9K	Buy	+800	New	+$12.3K	0.01%	293
2022 Q1	–	Sell	-800	Closed	-$5K	–	213
2021 Q4	$5K	Buy	+800	New	+$5.26K	﹤0.01%	351

Other funds holding CPRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Cassady Schiller Wealth Management's CPRX Position: Q4 2024 in Review

Cassady Schiller Wealth Management held its Catalyst Pharmaceutical (CPRX) position steady in Q4 2024 at 800 shares worth $16.7K. The position accounts for 0.01% of the portfolio, ranked #298.

Cassady Schiller Wealth Management first reported a position in CPRX in Q4 2021 and has held it in 10 quarters since. 336 funds tracked by Wall St. Rank hold CPRX as of Q4 2024.

Cassady Schiller Wealth Management held 800 shares of Catalyst Pharmaceutical worth $16.7K as of Q4 2024.
Cassady Schiller Wealth Management left its Catalyst Pharmaceutical share count unchanged in Q4 2024.
Catalyst Pharmaceutical made up 0.01% of Cassady Schiller Wealth Management's portfolio in Q4 2024, its #298 holding.
Cassady Schiller Wealth Management first reported a position in Catalyst Pharmaceutical in Q4 2021 and has held it in 10 quarters since.
336 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q4 2024.

Based on Cassady Schiller Wealth Management's 13F filing for Q4 2024, filed 10 Feb 2025.